ZIPRASIDONE HAD LITTLE INHIBITORY EFFECT ON CYP1A2, CYP2C9, CYP2C19, CYP2D6 AND CYP3A4, AND THUS WOULD NOT LIKELY INTERFERE WITH THE METABOLISM OF DRUGS PRIMARILY METABOLIZED BY THESE ENZYMES. AN ADDITIVE EFFECT OF ZIPRASIDONE AND OTHER DRUGS THAT PROLONG THE QT INTERVAL CANNOT BE EXCLUDED. THEREFORE, ZIPRASIDONE SHOULD NOT BE GIVEN WITH DOFETILIDE, SOTALOL, QUINIDINE, OTHER CLASS IA AND III ANTI-ARRHYTHMICS, MESORIDAZINE, THIORIDAZINE, CHLORPROMAZINE, DROPERIDOL, PIMOZIDE, SPARFLOXACIN, GATIFLOXACIN, MOXIFLOXACIN, HALOFANTRINE, MEFLOQUINE, PENTAMIDINE, ARSENIC TRIOXIDE, LEVOMETHADYL ACETATE, DOLASETRON MESYLATE, PROBUCOL OR TACROLIMUS. GIVEN THE PRIMARY CNS EFFECTS OF ZIPRASIDONE, CAUTION SHOULD BE USED WHEN IT IS TAKEN IN COMBINATION WITH OTHER CENTRALLY ACTING DRUGS. BECAUSE OF ITS POTENTIAL FOR INDUCING HYPOTENSION, ZIPRASIDONE MAY ENHANCE THE EFFECTS OF CERTAIN ANTIHYPERTENSIVE AGENTS.